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The mucosa, a mucus-secreting membrane, is linings of surface and cavities that are exposed 
to the external environment and internal organs. The mucosal immune system has a unique 
anatomy and physiology, which provides protection to an organism's various mucous 
membranes from invasion by potentially pathogenic microbes. It provides three main 
functions: protecting the mucus membrane against infection, preventing the uptake of 
antigens, microorganisms, and other foreign materials, and moderating the organism's 
immune response to that material. The mucosal epithelium forms the initial interface 
between the environment and host, and functions not only as a barrier but also as a sensor 
providing bidirectional communication with other resident mucosal lymphoid cells with the 
capacity to respond to pathogenic microbes and other injurious agents.  
It has become increasingly clear that epithelial cells play important roles not only in host 
defense and inflammation, but also in regulation of immune responses. The mammalian 
immune system is comprised of two branches, the innate immune system and the adaptive 
immune system, that work in tandem to provide resistance to infection. The innate immune 
cells, represented primarily by monocytes, macrophages, dendritic cells and granulocytes, 
are the first line of host defense and are responsible for immediate recognition and control 
of microbial invasion. In contrast, the adaptive immune system, represented by B and T 
lymphocytes, has a delayed response, which is characterized by clonal expansion of cells 
that bind to a highly specific antigen and have immunological memory [1]. Substantial new 
evidence now indicates that epithelial cells are central participants, as initiators, mediators 
and regulators, in the innate and adaptive immune responses, as well as in the transition 
from innate immunity to adaptive immunity.    
                                                 
* Corresponding Author 
www.intechopen.com
 Advances in Ophthalmology 
 
50
This new concept has been recently generated from studies mainly in skin and airway 
epithelial cells. In addition to its function as a physical barrier, human skin has been shown 
to be an important immune organ displaying various defense mechanisms, which can be 
divided into three major functional compartments: natural epithelial defense, innate 
immunity and antigen-elicited adaptive immunity [2-4]. Airway epithelial cells have been 
recognized to be at the interface of innate and adaptive immunity [5-7]. Airway epithelial 
cells produce antimicrobial host defense molecules and proinflammatory cytokines and 
chemokines in response to microbial pathogens. Recruitment of immune cells, including 
dendritic cells, T cells and B cells into the proximity of epithelium results in the 
enhancement of adaptive immunity through interactions with epithelial cells. Epithelial cells 
are also responsible for mucus production in both protective immune responses and allergic 
airway inflammatory diseases. The crucial roles of epithelial cells in the innate and adaptive 
immune responses for host defense have also been recognized in other epithelia, including 
gastrointestinal mucosa [8-10] and ocular surface [11-13]. This chapter is focused on recent 
advances of this new concept that mucosal epithelium plays a central role in initiating and 
regulating innate and adaptive immune responses in ocular inflammatory diseases, based 
on literature review and our new findings. These novel breakthroughs in mucosal 
immunology would facilitate new therapeutic strategies for treating ocular inflammatory 
diseases. 
2. Toll-like receptors and ocular mucosal innate immunity  
The innate immune response relies on evolutionarily ancient germline-encoded receptors, 
the pattern recognition receptors (PRRs) [14], which recognize highly conserved microbial 
structures (Table 1). PRRs recognize microbial components, known as pathogen-associated 
molecular patterns. A breakthrough in the understanding of the ability of innate immune 
system to rapidly recognize pathogens occurred with the discovery of the Toll-like receptors 
(TLRs), which is the most important family among the PRRs. At least 10 human TLRs have 
been identified to date. Each TLR has unique ligand specificity. In general, TLRs 1, 2, 4, 5 
and 6 present on the cell plasma membrane and respond to a variety of components of 
bacteria and fungi (Table 1); and TLRs 3, 7, 8 and 9 mainly present on endosomal 
membranes inside cells and recognize viral nucleic acids [12]. Among 4 types of 
transmembrane proteins structurally, TLRs are single-pass type I transmembrane proteins 
with leucine rich repeats in the extracellular domain for ligand recognition, and a Toll/IL-1 
receptor (TIR) domain in the cytoplasmic portion for intracellular signaling [12, 15-17]. TLRs 
are expressed on immune cells that are most likely to first encounter microbes, such as 
neutrophils, monocytes, macrophages, and dendritic cells [15]. Ligand recognition by TLRs 
facilitates the dimerisation of TLRs that triggers the activation of signaling pathways, which 
originates from the cytoplasmic TIR domain, and culminates in the activation of the nuclear 
transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), 
which leads to the expression of pro-inflammatory molecules, such as TNF-ǂ, IL-1ǃ, IL-6 
[16, 18-20]. In addition to innate immune cells, an array of TLRs is expressed by epithelial 
cells at interfaces between host and environment including that of the skin [2, 21], 
respiratory tract [5, 6], gastrointestinal tract [9], and ocular surface [12, 13]. Strategic 
expression of TLRs at such host/environment interfaces appears to play an important role in 
the first line of defense against microbial invasion at these sites.  
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TLR  Microbial components Ligands used for study 
TLR1/TLR2 Triacylated lipopeptide (LP) Pam3CSK4 (1-100 μg/ml) 
TLR2*    Bacterial lipoprotein  
 Peptidoglycan peptidoglycan-BS (1-50 μg/ml) 
 lipoteichoic acid LTA-SA (0.1-10 μg/ml) 
 Zymosan (fungi) Zymosan (1-100 μg/ml) 
TLR3  Double stranded RNA (viruses dsRNA) Poly I:C (5-50 μg/ml) 
TLR4  LPS (Gram negative bacteria) LPS (1-50 μg/ml) 
 Bacterial HSP60  
 Respiratory syncytial virus coat protein  
TLR5  Flagellin (flagellated bacteria) Flagellin-ST (1-25 μg/ml) 
TLR6/TLR2 Diacylated lipopeptides FSL-1 (0.1-10 μg/ml) 
TLR7 Imidazoquinolone antiviral drug Imiquimod (R837, 1-50 μg/ml ) 
TLR8 Single stranded RNA (viruses ssRNA) ssRNA40 (0.1-10 μg/ml) 
 Imidazoquinolone antiviral drug  
TLR9  Unmethylated CpG motifs of bacterial DNA C-CpG-ODN (1-50 μg/ml) 
TLR10  Unknown  
* TLR2 forms heterodimers with TLR1 and TLR6: TLR1 associates with TLR2 to recognize tri-acyl 
lipopeptides; TLR6/TLR2 heterodimer recognizes diacyl lipopeptides. 
Table 1. Human Toll-like receptors (TLRs) and their microbial ligands 
Ocular mucosal epithelial cells have been identified to express an array of functional TLRs 
[12, 13]. The production of pro-inflammatory cytokines, chemokines and antimicrobial 
peptides is stimulated via TLR2 by corneal epithelial cells exposed to yeast zymosan [22] 
and peptidoglycan of Staphylococcus aureus [23]. This pathway may have a role in the 
pathogenesis of Gram positive bacterial keratitis. Signaling through TLR9 appears 
important in P. aeruginosa keratitis, and silencing TLR9 signaling reduces inflammation, but 
likely contributes to decreased bacterial killing in the cornea [24]. Stimulation of TLR3 can 
induce the expression of proinflammatory cytokines, chemokines and antiviral genes that 
help to defend the cornea against viral infection [25, 26]. However, the distinctive role of 
ligand-stimulated TLR signaling in epithelium on regulation of innate and adaptive 
immunity remains to be elucidated. 
3. Ocular epithelial cytokine TSLP links innate and adaptive immunity via Th2 
inflammatory responses  
Compelling evidence has been recently provided that thymic stromal lymphopoietin (TSLP) 
represents a key initiator of allergic inflammation at the interface of epithelial and dendritic 
cells, and TSLP may have a determinant role in the initiation and maintenance of the allergic 
immune response in atopic dermatitis and asthma [27-31]. Skin-derived TSLP was found to 
trigger progression from epidermal-barrier defects to asthma, the atopic march, in mice  
[31, 32].  
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TSLP is a 140-amino acid IL-7-like 4-helix bundle cytokine that was first isolated from a 
murine thymic stromal cell line and shown to support B-cell development in the absence of 
IL-7 [33]. Mouse and human TSLP share a poor homology of 43% amino acid identity. The 
human TSLP gene is localized in chromosome 5q22, not far from the gene cluster encoding 
for all the Th2 cytokines, IL-4, IL-5 and IL-13 [34]. The TSLP receptor (TSLPR) complex 
consists of a TSLP binding chain and the IL-7 receptor ǂ chain (IL-7Rǂ). Like TSLP, human 
and mouse TSLPR share approximately 40% amino acid identity. By interacting with the 
heterodimeric receptor TSLPR/IL-7Rǂ, TSLP appears to initiate phosphorylation  of signal 
transducer and activator of transcription (STAT) 3 and STAT-5 [27, 35]. 
It was demonstrated that epithelial cell-derived TSLP could strongly activate human 
myeloid dendritic cells to mature dendritic cells that produce OX40 ligand (OX40L) in the 
absence of IL-12 to induce an inflammatory Th2 response characterized by high level of pro-
inflammatory cytokine TNF-ǂ with low level of anti-inflammatory cytokine IL-10, distinct 
from the regulatory Th2 responses characterized by low TNF-ǂ and high IL-10 production 
[27, 28]. This suggests that TSLP represents a key initiator of allergic inflammation at the 
interface of epithelial cells and dendritic cells. TSLP was also demonstrated to direct the 
innate phase of allergic immune responses through activating mast cells. Therefore, TSLP 
and OX40L may represent important targets for intervention in the initiation of allergic 
inflammatory responses.  
Epithelial cells appear to be the major potential producer of TSLP in both mice and humans, 
although fibroblasts, smooth muscle cells, and mast cells all have the potential to produce 
TSLP [35, 36]. The expression of TSLP by epithelial cells has been recently shown to be 
stimulated by microbial ligands, inflammatory and Th2 cytokines [37-39]. Using ocular 
mucosal epithelium as a model, Li and associates [40] have evaluated the expression and 
production of TSLP by primary human corneal epithelial cells in response to 11 extracted or 
synthetic microbial components that are ligands of TLRs 1-9 (Table 1). As shown in Figure 1A, 
TSLP expression and production were found to be largely induced by the ligands to TLRs 3, 5 
and 6, which were polyinosinic-polycytidylic acid (polyI:C), flagellin and FSL-1, respectively, 
representing viral dsRNA and the bacterial components flagellin and lipopeptides. PolyI:C 
and flagellin, the major TSLP inducers, stimulated TSLP production to 67- and 19-fold, 
respectively. The TSLP mRNA reached the peak levels rapidly in 4 hours in response to these 
ligands. The specificity of this response was confirmed when respective antibody against TLR3 
or TLR5 significantly blocked TSLP expression induced by polyI:C and flagellin, respectively. 
The pattern of TLR-dependant TSLP induction indicates that human corneal epithelial cells are 
able to rapidly initiate an innate immune response to virus or bacteria through TLR-mediated 
pathways. TSLP was also moderately induced by pro-inflammatory cytokines at both mRNA 
and protein levels. TNF-ǂ or IL-1ǃ induced a concentration dependent increase in the TSLP 
mRNA and protein, but their stimulatory effects were much weaker than that of polyI:C and 
flagellin, which stimulated TSLP protein production over 15- and 4-fold higher, respectively, 
than TNF-ǂ. These data suggest that TSLP induction is mainly through a TLR-dependant 
innate immune response to microbes in human ocular epithelium.  
IL-4 and IL-13, the major cytokines secreted by Th2 cells, not only moderately induced TSLP 
mRNA and protein, but also strongly synergized with microbial ligands, such as polyI:C, or 
pro-inflammatory cytokine TNF-ǂ to promote TSLP expression and production  (Figure 1B). 
This synergized induction of TSLP was further confirmed in an ex vivo experiment model 
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using fresh human corneal epithelial tissues (Figure 1C). These findings demonstrate that 
adaptive immunity-derived Th2 cytokines are capable of amplifying the TSLP expression 
and production by the corneal epithelium, which in turn has the capability of priming Th2 
cell differentiation through dendritic cell activation [27, 28]. These findings suggest that 
blocking TSLP could be a novel strategy for treatment of allergic diseases or other TSLP-
driven conditions. 
 
Fig. 1. TLR-mediated induction of TSLP by microbial ligands, TNF-ǂ and Th2 cytokines.  
A. TSLP induction in HCECs. The confluent primary HCECs were incubated with 50µg/ml 
polyI:C or 10µg/ml of Pam3CSK4, peptidoglycan (PGN), LTA, Zymosan, LPS, flagellin,  
FSL-1, R837, single stranded RNA (ssRNA40) or C-CpG-ODN for 4 hours for TSLP mRNA 
expression by RT-qPCR, or for 48 hours for TSLP protein in the culture supernatants by ELISA; 
B. TSLP induction in an ex vivo model of human corneal tissues. A fresh corneoscleral tissue 
was cut into 4 equal size pieces. Each quarter of corneal tissue was placed into a well of 8-
chamber slides in 150 µl of serum-free SHEM medium without or with polyI:C (50 µg/ml) or 
TNF-ǂ (20 ng/ml) in the presence of IL-4 or IL-13 (100 ng/ml) for 24 hours. The culture 
supernatants were used for TSLP ELISA. Results shown are mean ± SD of 3 independent 
experiments. * p < 0.05; ** p < 0.01; *** P < 0.001. C. The corneal tissues were prepared for 
cryosections for TSLP immunohistochemical staining with isotype IgG as negative control. 
Although the recognition of different ligands by specific TLRs leads to activation of an 
intracellular signaling cascade in a myeloid differentiation primary response gene 88 
(MyD88)-dependent or independent fashion, all TLRs share NF-κB signal transduction 
pathways for activation of the transcription factors [20]. TNF-ǂ is also well known to 
promote activation of the NF-κB signaling pathway [41]. TSLP induction has been observed 
through NF-κB activation in airway epithelial cells [30] and synovial fibroblasts [42]. As 
evaluated by Western blot analysis and immunofluorescent staining, NF-κB was found to be 
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dramatically activated in corneal epithelial cells exposed to polyI:C, flagellin or TNF-ǂ for 4 
hours. This activation was evidenced by nuclear translocation of p65 protein, one of the two 
proteins in NF-κB heterodimer. This p65 nuclear translocation and TSLP induction, 
stimulated by polyI:C, flagellin or TNF-ǂ were markedly blocked by TLR3, TLR5 or TNF-ǂ 
specific antibody, respectively, and also by quinazoline, a NF-κB activation inhibitor [40]. 
These findings confirm that TSLP is mainly induced by microbial components, 
proinflammatory cytokines and Th2 cytokines in human corneal epithelial cells via TLR and 
NF-κB signaling pathways, suggesting that epithelium-derived TSLP links the innate and 
adaptive immune responses, 
4. TSLP/OX40L/OX40 signaling initiates Th2-dominant allergic conjunctivitis 
Allergic diseases like seasonal allergy, asthma, atopic dermatitis, affect up to 20-30% of the 
population in industrialized countries, and up to 50% of these individuals reporting ocular 
allergic manifestations [43-45]. The incidence of allergies has increased steadily over the past 
30 years. Th2-dominant hypersensitivity is a major contributor to allergic inflammatory 
diseases, but the underlining mechanism for initiation of this adaptive immune disorder by 
mucosal epithelia remains a relative mystery. The molecular triggers for Th2 allergic 
inflammation were not clear until studies identified a novel epithelium-derived pro-allergic 
cytokine TSLP, which activates myeloid dendritic cells (DCs) to produce OX40 ligand 
(OX40L) that triggers a Th2 inflammatory response. TSLP has been identified as a key 
initiator in the development of human allergic disease [31, 46, 47], including asthma, atopic 
dermatitis and allergic conjunctivitis, a triad of common atopic IgE-dependent allergic 
diseases [48]. The direct link between TSLP expression and the pathogenesis of atopic 
dermatitis and asthma in vivo has been demonstrated [29]. TSLP was found to be highly 
expressed by keratinocytes in skin lesions of atopic dermatitis and was associated with 
dendritic cell activation in situ [49]. Evidence associating TSLP with human asthma has also 
been reported [29, 32]. Patients suffering from one member of the triad often show 
symptoms of one or both of the other members, suggesting a common genetic or initiating 
element in these diseases [31]. 
Using a well characterized murine model of experimental allergic conjunctivitis (EAC) 
induced by short ragweed (SRW) pollen [50, 51], Li and colleagues observed that the 
repeated topical challenges with ragweed pollen allergen generated typical signs of allergic 
conjunctivitis in the pollen-sensitized BALB/c mice, which developed lid edema, 
conjunctival redness, chemosis, and tearing, as well as frequent scratching of the eye lids 
[52]. They found that TSLP mRNA expression was significantly upregulated in the corneal 
and conjunctival epithelia from mice sensitized and challenged with pollen when compared 
with phosphate buffered saline (PBS) alone and untreated normal controls. 
Immunohistochemical staining confirmed an increase in TSLP production in the eyes 
challenged with SRW pollen. As shown in Figure 2A, the corneal and conjunctival epithelia 
in EAC BALB/c mice displayed much stronger TSLP staining throughout the entire 
epithelium, especially the superficial epithelial layers of the conjunctiva, than the PBS-
treated control. These data indicate the stimulated TSLP mRNA expression and protein 
production by ocular surface epithelia in the SRW-induced EAC murine model. 
The accumulation of CD11c positive (CD11c+) dendritic cells on the ocular surface was 
detected in this EAC model by reverse transcription and quantitative real-time polymerase  
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Fig. 2. The stimulated production of TSLP signaling proteins and Th2-dominant 
inflammation in SRW-induced EAC model requires TLR4 and MyD88. Top panel: The 
representative images showing immunohistochemical staining of epithelial TSLP, markers 
for dendritic (CD11c) and T cells (CD4), and Th2 cytokines (IL-4, IL-5 and IL-13) on cornea 
and conjunctiva (Conj) of wild type and Tlr4 deficient BALB/c mice challenged by SRW 
pollen, with PBS-treated mice as controls (A), and of C57BL/6 based wild type MyD88+/+ 
and knockout MyD88-/- mice challenged by SRW pollen, with PBS-treated mice as controls 
(C). Bottom panel: The representative images showing immunofluorescent staining of TSLP 
activated signals, TSLPR, OX40L and OX40 on cervical lymph nodes (CLN) of wild type and 
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Tlr4 deficient BALB/c mice challenged by SRW pollen with PBS-treated mice as controls (B), 
and of C57BL/6 based wild type MyD88+/+ and knockout MyD88-/- mice challenged by SRW 
pollen, with PBS-treated mice as controls (D). Bar: 20µm; Arrows: red or red brown positive 
staining signals. 
chain reaction (RT-qPCR) and immunostaining. The increased mRNA levels of CD11c, 
TSLPR and OX40L were observed in ocular surface, especially in conjunctival tissues, where 
their transcripts increased to 4-10 fold, respectively (P< 0.05 or <0.01), from SRW pollen-
challenged mice, compared with PBS controls. The large amount of CD11c+ dendritic cells 
was accumulated in the ocular surface of the pollen challenged eyes, primarily in the stroma 
subjacent to the conjunctival epithelia, in EAC mice, but not in the control mice treated with 
PBS (Figure 2A). These results suggest that ocular surface was infiltrated with TSLP 
activated dendritic cells that express TSLPR and produce OX40L in the EAC mice. 
Th2-dominant inflammatory response was clearly observed on ocular surface in the mice 
challenged by pollen. The infiltration of T lymphocytes was evidenced by the increased CD4 
mRNA expression and a markedly increased number of CD4 immunopositive (CD4+) cells 
in the ocular surface, especially in the conjunctiva, of EAC mice (Figure 2A), when 
compared with PBS control mice. These CD4+ T cells appear to be Th2 lineage because the 
transcripts of three key Th2 cytokines, IL-4, IL-5 and IL-13, were all found to be expressed at 
significantly higher levels in corneal and conjunctival tissues from the EAC mice than the 
PBS controls. Immunostaining data confirmed that the IL-4, IL-5 and IL-13-producing Th2 
cells were largely infiltrated in conjunctival stroma (Figure 2A).  
To confirm the TSLP signaling in SRW pollen-induced EAC mice, the ocular surface 
draining cervical lymph nodes (CLN) were collected for evaluation (Figure 3A). Compared 
with PBS controls, the mRNA levels of TSLPR and OX40L were significantly stimulated to 
7.5 and 4.1 fold respectively (both P<0.01) while CD11c expression only slightly increased in 
CLN from EAC mice, indicating CD11c+ DCs were markedly activated by ocular surface 
epithelia-derived TSLP. The mRNA levels of OX40 (3.4 fold, P<0.05) and Th2 cytokines, IL-4, 
IL-5 and IL-13 (13.2, 12.8 and 5.5 fold, respectively, all P<0.01), significantly increased while 
CD4 expression was not changed in the CLN from EAC mice, indicating naive CD4+ T cells 
were largely differentiated to Th2 cells that might be primed by OX40L produced by TSLP 
activated dendritic cells [28]. The increased TSLPR+, OX40L+ and OX40+ cells in the draining 
CLN of the pollen challenged EAC mice were further confirmed by immunofluorescent 
staining that showed dramatically increased immunoreactivity of these 3 signaling proteins 
at cell membrane and cytoplasm in CLN (Figure 2B). All these results demonstrate that 
TSLP/OX40L/OX40 signaling plays a critical role in the development of Th2-dominant 
allergic inflammation in pollen induced EAC model in BALB/c mice, suggesting that TSLP 
signaling molecules could be novel therapeutic targets to treat allergic inflammatory 
disease. 
5. Cutting edge breakthrough: Short ragweed pollen triggers ocular allergic 
inflammation through TLR4-dependent innate immune response 
Although there have been numerous studies on the development of allergen-induced 
inflammation, the mechanisms leading to resolution of allergic inflammation remain poorly 
understood. This represents an important knowledge gap and potential challenge because 
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failure to resolve allergen driven inflammation potentially leads to recurrent or chronic allergic 
diseases. Pollen, a ubiquitous allergen, affects a large population of allergic patients. Pollen is 
the trigger of seasonal rhinitis, conjunctivitis and asthma, as well as an exacerbating factor of 
atopic dermatitis. However, the underlying molecular mechanism by which pollen induces 
Th2-dominant allergic inflammation via epithelial innate immunity pathways is largely 
unknown. Substantial evidence now indicates that epithelial cells are central participants in 
innate and adaptive immune responses [4, 5, 7]. Based on the observation that we and other 
groups have made [40, 53, 54] that TSLP is mainly induced via TLR mediated innate response 
in epithelia exposed to microbial products, we hypothesized that pollen, such as Ambrosia 
artemisiifolia short ragweed (SRW), the most widespread plant in North America, may serve 
as a functional TLR4 agonist that induces production of a proallergic cytokine TSLP via innate 
immune response to trigger Th2-dominant allergic inflammation. To uncover the novel 
phenomenon and molecular signaling pathways involved in pollen induced allergic 
inflammation, a comprehensive set of experiments has been conducted using a well-
characterized murine model of allergic conjunctivitis induced by SRW pollen in BALB/c, TLR4 
deficient and MyD88 knockout mice, as well as a murine topical ocular surface challenge 
model and a culture model of primary human corneal epithelial cells exposed to an aqueous 
extract of defatted SRW pollen. 
TLR-mediated TSLP induction has been recognized [39, 53, 54]. We have demonstrated that 
TSLP was largely induced by specific TLR ligands in human corneal epithelial cells [40]. 
MyD88 is a universal adapter protein necessary for response to all TLRs except TLR3 [55, 
56]. Tlr4-deficient (Tlr4-d, C.C3-Tlr4Lps-d/J) and MyD88 knockout (MyD88-/-) mice have 
been used to identify TLR4 mediated signaling [57, 58]. To explore whether SRW pollen 
stimulates TSLP through TLR4-dependent innate response, we sensitized and topically 
challenged the wild-type BALB/c, Tlr4-d (Jackson Laboratory, Bar Harbor, ME) and MyD88-
/- mice (gifts from Dr. Shizuo Akira, Research Institute for Microbial Disease, Osaka 
University, Japan) with SRW pollen. 
Compared with wild-type BALB/c mice, the ocular allergic signs, stimulated 
TSLP/OX40L/OX40 signaling and Th2-dominant inflammatory response by ocular mucosa, 
especially conjunctival tissues, were dramatically reduced or eliminated in BALB/c based 
Tlr4-d mice. As shown in Figure 3A, the mRNA levels of TSLP, OX40L, OX40 and Th2 
cytokines (IL-4, IL-5 and IL-13) were significantly stimulated in cornea, conjunctiva and 
draining CLN from wild-type BALB/c, but not in those from Tlr4-d mice. The 
immunostaining results confirmed that SRW pollen did not stimulate TSLP and its 
downstream molecules or a Th2 response in ocular mucosal tissues (Figure. 2A) and 
draining CLN (Figure. 2B) of Tlr4-d mice. These findings suggest that TLR4-dependent 
TSLP signaling was involved in the SRW pollen induced allergic inflammation. 
The SRW topical challenges triggered the typical allergic signs and scratching behavior in 
wild type MyD88+/+ mice, although less severe than BALB/c mice. The expression of TSLP 
and its signaling molecules, TSLPR, OX40L and OX40, as well as Th2 cytokines IL-4, IL-5 
and IL-13 was significantly stimulated in the cornea, conjunctiva and CLN from SRW 
challenged wild type MyD88+/+ mice at both mRNA (Figure. 3B) and protein levels (Figure 
2C, 2D). Clinical allergic signs and stimulated production of TSLP signaling molecules 
(TSLPR, OX40L and OX40) and Th2 cytokines (IL-4, IL-5 and IL-13) were dramatically 
reduced or eliminated in SRW challenged MyD88-/- mice as evaluated by RT-qPCR (Figure 
www.intechopen.com
 Advances in Ophthalmology 
 
58
3B) and immunostaining (Figure 2C, 2D). These findings suggest that MyD88 pathway is 
involved in the TLR4-dependent TSLP signaling induced by SRW pollen. 
 
 
Fig. 3. The stimulated expression of TSLP signaling molecules and Th2 cytokines in SRW-
induced EAC model requires TLR4 and MyD88. The mRNA expression of proallergic 
cytokine TSLP, its downstream signals in dendritic (TSLPR, OX40L, & CD11c) and T cells 
(OX40 & CD4), as well as Th2 cytokines (IL-4, IL-5 and IL-13) by corneal epithelium, 
conjunctiva and cervical lymph nodes in wild type and Tlr4 deficient BALB/c mice 
sensitized and topically challenged by SRW with PBS-treated mice as controls (A), and in 
C57BL/6 based wild type MyD88+/+ and knockout MyD88-/- mice, sensitized and topically 
challenged by SRW pollen, with PBS-treated mice as controls (B). The mRNA levels are 
presented as relative fold in EAC mice over the controls, which were evaluated by RT and 
real-time qPCR using TaqMan gene expression assay system with GAPDH as an internal 
control. Results shown are the Mean ± SD of four independent experiments. *P<0.05, 
**P<0.01; n=4, compared with PBS controls; P<0.05, P<0.01, n=4, compared with wild 
type mice. 
To confirm that SRW pollen directly stimulates TSLP production by ocular mucosal 
epithelia through TLR4-dependent innate immunity pathway, we created a topical 
challenge murine model using an aqueous extract of defatted SRW pollen (SRWe) at 
150µg/5µl/eye for 4-24 hours. TSLP mRNA was induced as early as 4 hours and reached 
peak levels at 8 hours, and TSLP protein levels increased in 24 hours in ocular epithelia 
exposed to SRWe. As shown in Figure 4 A & B, SRWe significantly stimulated TSLP mRNA 
by 2 fold in corneal and conjunctival epithelia (Both P<0.05), and its protein levels by 3.2 
fold (from 150.2±37.6 pg/mg cellular protein to 480.00±89.6 pg/mg) in cornea epithelia and 
2.2 fold (from 128.6±29.8 pg/mg to 281.6±19.3 pg/mg) in conjunctiva in BALB/c mice when 
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compared with untreated or PBS-treated controls. The SRWe-stimulated TSLP were 
significantly decreased at both mRNA and protein levels by TLR4 blocker, a rat anti-mouse 
TLR4 antibody, but not by its isotype rat IgG2a.  
The SRWe topical challenge did not increase TSLP mRNA (Figure 4C) and protein levels 
(Figure 4D) in corneal and conjunctival epithelia of Tlr4-d mice. Similarly, a TLR4 agonist 
lipopolysaccharides (LPS, 5µg/5µl/eye) stimulated TSLP production by corneal and 
conjunctival epithelia in BALB/c mice, but not in Tlr4-d mice. Furthermore, we applied this 
topical challenge model to MyD88 knockout mice and their wild type controls. SRWe  
 
Fig. 4. Aqueous extract of defatted SRW pollen (SRWe) induces TSLP expression and 
production by murine ocular surface epithelia through TLR4- and MyD88-dependent innate 
immunity pathway. A, B. BALB/c mice were topically instilled with SRWe at 
150µg/5µl/eye for 6 or 24 hours for TSLP mRNA (A) or protein (B) respectively, without or 
with pre-instilled rat anti-mouse TLR4 antibody (1µg/5µl/eye) or its isotype rat IgG2a. 
Untreated (UT) and PBS-treated mice were used as controls. Corneal epithelium and 
conjunctiva were harvested for TSLP mRNA and protein by RT-qPCR and ELISA 
respectively. C, D. TSLP mRNA (C) and protein (D) induction by topically challenged SRWe 
or LPS (5µg/5µl/eye) in wild type and Tlr4-d BALB/C mice, with untreated or PBS-treated 
mice as controls. E, F. TSLP mRNA (E) and protein (F) induction by topically challenged 
SRWe or LPS in wild type MyD88+/+ and knockout MyD88-/- mice, with untreated or PBS-
treated mice as controls. Results shown are the Mean ± SD of four independent experiments. 
*P<0.05, **P<0.01; n=4, compared with PBS controls. 
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promoted TSLP production by ocular epithelia at both mRNA (Figure 4E) and protein levels 
(Figure 4F) only in MyD88+/+ mice, but not in MyD88-/- mice, a similar pattern to that 
observed following LPS topical challenge. Taken together, these data demonstrated that 
SRWe directly stimulates TSLP production by ocular mucosal epithelia via a TLR4-
dependent innate pathway. 
To explore whether this phenomenon occurs in humans, we investigated TSLP expression in 
human corneal epithelium. TSLP mRNA was upregulated at 4 hours and its protein was 
detected at 24 hours in human corneal epithelial cells (HCECs) exposed to SRWe, which is 
consistent with our previous report [40]. TSLP induction at mRNA (Figure 5A) and protein 
levels (Figure 5B) was concentration-dependently stimulated by SRWe in primary HCECs. 
TSLP protein was barely detectable (4.83±1.60 pg/ml) in the supernatant of normal HCEC 
cultures. SRWe at 10µg/ml increased the TSLP protein to 48.92±4.23 pg/ml (P<0.01), the 
levels comparable to that stimulated by 10ng/ml of TNF-ǂ in HCECs [40]. The SRWe 
(10µg/ml)-stimulated TSLP mRNA was significantly blocked by pre-incubation of cells with 
10µg/ml of neutralizing monoclonal antibody against human TLR4, but not by its isotype 
mouse IgG2a k (Figure 5C). Furthermore, SRWe stimulated TSLP expression was also 
significantly inhibited by quinazoline, a NF-κB Activation Inhibitor (Figure 5C). These 
findings were confirmed by detection of increased TSLP protein levels as shown in Figure 
5D. These data demonstrate that SRW induces TSLP production in human corneal epithelial 
cells through TLR4 and NF-κB innate signaling pathways. 
 
Fig. 5. SRWe induces TSLP expression and production by human corneal epithelial cells 
(HCECs) through TLR4 and NF-κB signaling pathways. A, B. Confluent cultures of primary 
HCECs were treated with 0.1 to 50 µg/ml of SRWe for 4 hours for TSLP mRNA or 48 hours 
for TSLP protein in the supernatants. C, D. HCECs were pre-incubated with mouse TLR4 
antibody (10µg/ml), isotype mouse IgG2a k, or NF-κB activation inhibitor quinazoline 
(NFkB-I, 10µM) for 1 hour before adding 10µg/ml SRWe for 4 hours for TSLP mRNA or 48 
hours for TSLP protein in the supernatants. Results shown are the Mean ± SD of four 
independent experiments. *P<0.05, **P<0.01; n=4. 
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Traditionally, TLRs recognize conserved microbial components as ligands or agonists. Recent 
studies have revealed that TLR4 recognizes a wider variety of ligands than previous thought. 
In addition to its first identified ligand, bacterial LPS, TLR4 was found to recognize certain 
viral proteins such as the F protein from respiratory syncytial virus and mouse mammary 
tumor virus. Not limited to pathogen-associated molecular patterns (PAMP), TLR4 responds 
to human endogenous structural proteins derived from tissue injury or during inflammation, 
the damage-associated molecular patterns (DAMP), such as type III repeat extra domain A of 
fibronectin, oligosaccharides of hyaluronic acid, human heat-shock protein Hsp60 and Hsp70 
(see review [59]). A few reports have revealed the potential for protein extracts from plants 
and herbs to activate TLR4, such as taxol, an antitumor agent derived from the Yew plant [60], 
and aqueous extract of Rhodiola imbricata rhizome, a medicinal plant [61]. 
In conclusion, we have for the first time uncovered a novel phenomenon and a unknown 
mechanism that short ragweed pollen, serving as a functional TLR4 agonist, induces 
TSLP/OX40L/OX40 signaling to trigger Th2-dominant allergic inflammation via TLR4-
dependent innate immunity pathways [62]. These novel findings shed light on the 
understanding of innate mucosal epithelial immunity involved in allergic inflammation, and 
may create new therapeutic targets to cure allergic disease. 
6. Epithelium-derived interleukin 33 initiates allergic inflammation 
The IL-1 receptor family has several members, including the classical IL-1 receptor (IL-1R) 
and the IL-18 receptor (IL-18R). In 1989, one member of the family, ST2, a protein encoded 
by IL-1 receptor-like 1 (IL-1RL1) gene, was identified as an orphan receptor [63]. 
Investigation into the function of ST2 revealed its participation in inflammatory processes, 
particularly regarding mast cells, type 2 CD4+ T helper cells and the production of Th2-
associated cytokines. In fact, ST2 was characterized as a specific cellular marker that 
differentiated Th2 from Th1 T cells. Clinical and experimental observations led to the 
association of ST2 with disease entities such as asthma, pulmonary fibrosis, rheumatoid 
arthritis, collagen vascular diseases and septic shock [64]. In 2005, the discovery of IL‑33 as a 
ST2 ligand provided new insights into ST2 signaling [65]. By binding to ST2 receptor, IL-33 
can activate Th2 cells and mast cells to secrete the proinflammatory and Th2 cytokines and 
chemokines that lead to severe pathological changes in mucosal organs [66]. 
IL-33 is produced mainly by epithelial and endothelial cells, fibroblast, and others [66-68]. 
IL-33 expression has been found to be up-regulated by stimulation with inflammatory 
cytokines, TNF-ǂ and IL-1ǃ [69]. However, the expression and regulation of IL-33 by 
mucosal surface epithelia has not been well elucidated. Using fresh donor corneal tissues 
and primary HCECs, we recently observed that IL-33 is mainly expressed by epithelium and 
largely induced by microbial products through TLR and NF-κB signaling pathways [70]. 
The findings suggest that the mucosal epithelial cell-derived cytokine IL-33 may play an 
important role in allergic inflammatory diseases through innate immune responses. 
As shown in Figure 6A, IL-33 expression and production were largely induced by polyI:C, 
lipopolysaccharides (LPS), flagellin, FSL-1 and R837, the ligands for TLR3, -4, -5, -6 and -7, 
representing viral dsRNA and the bacterial components flagellin and lipopeptides, 
respectively. PolyI:C and flagellin were major IL-33 inducers, stimulating IL-33 production 
by 7- and 4-fold, respectively, with the peak mRNA levels at 8 hours by HCECs. The IL-33 
induction by these 2 ligands was further confirmed using an ex vivo donor corneal tissue 
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model (Figure 6B). The specificity of TLR-dependent response by HCECs was also 
confirmed when an antibody against TLR3 or TLR5 significantly inhibited IL-33 expression 
by polyI:C or flagellin respectively (Figure 6C). The pattern of TLR-dependent IL-33 
induction indicates that HCECs are able to rapidly initiate an innate immune response to 
virus or bacteria, and play an important role in allergic inflammatory disease. 
 
Fig. 6. TLR-dependent induction of IL-33 by microbial ligands in human corneal epithelium. 
A. IL-33 mRNA and protein levels induced by primary human corneal epithelial cells 
(HCECs) exposed to 50μg/ml polyI:C or 10μg/ml of Pam3CSK4, peptidoglycan (PGN), 
polyI:C, LPS, flagellin, FSL-1, R-837, ssRNA40 or C-CpG-ODN for 8 or 48 hours, evaluated 
by quantitative real-time PCR or ELISA, respectively. Results shown are the mean ± SD of 
four independent experiments. *P< 0.05; **P < 0.01. B. The immunohistochemical staining 
showing IL-33 induction in an ex vivo human corneal tissues by polyI:C (50μg/ml) or 
flagellin (10μg/ml) for 24 hours with isotype IgG as a negative control. C. TLR and NF-κB 
signaling pathways involved in IL-33 induction by polyI:C or flagellin in HCECs exposed to 
polyI:C (50μg/mL) or flagellin (10μg/mL) in the absence or presence of preincubated rabbit 
TLR3Ab (10μg/mL), TLR5Ab (10μg/mL), BAY11-7082 (10μM) or quinazoline (10μM) for 1 
hour, and Pepinh-MYD (40μM) or Pepinh-TRIF (40μM) for 6 hours. The cultures treated by 
ligands for 8 hours for IL-33 mRNA, or for 48 hours for IL-33 protein by ELISA and by 
Western blot with ǃ-actin as control (D). Results shown are the mean ± SD of four 
independent experiments. *P< 0.05; **P < 0.01. 
IL-33 is an extracellular inflammatory cytokine while it also acts as a nuclear transcription 
factor [71]. It has been shown that IL-33 is mainly localized to the nucleus of endothelial cells 
and bound to chromatin. IL-33 mRNA is primarily translated and synthesized in vivo as a 
30-kDa precursor, a pro-IL-33 protein. As a member of IL-1 super family and like IL-1 and 
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IL-18, pro-IL-33 protein sequence does not have a signal peptide that directs it for secretion 
via the ER–Golgi pathway [66, 72]. Like pro-IL-1ǃ, human pro-IL-33 was reported to be 
cleaved by caspase-1 to generate active form, an 18-kDa fragment (mature IL-33), which is 
sufficient to activate signaling via the IL-33 receptor ST2. Recombinant mature IL-33 has 
been known to induce Th2-associated cytokines and inflammatory cytokines via its receptor, 
ST2 [72, 73]. However, processing of pro-IL-33 in vivo has not been clarified yet. It is not 
clear whether caspase-1 cleavage of pro-IL-33 occurs in vivo and whether, as for IL-1ǃ, this 
cleavage is a prerequisite for IL-33 secretion and bioactivity. 
Our data have showed that no significantly changes of IL-33 protein levels can be detected 
by ELISA in the culture supernatants, other than in cell lysate, of the HCECs. IL-33 protein 
levels significantly increased in the cell lysate, but not in the culture supernatants, of HCECs 
exposed to polyI:C or flagellin for 24-48 hours, when compared with the untreated control. 
However, the stimulated cellular IL-33 protein was released outside the cells into culture 
supernatant after co-incubation with ATP for additional 30 minutes, as evaluated by ELISA 
and Western blot analysis [70]. The finding supports a notion that caspase 1-dependant 
activation may involved in the release and secretion of IL-33 protein since ATP has been 
known to activate caspase-1 through triggering the P2X7 receptor [74]. Further studies are 
necessary to clarify the underlining mechanism.  
As shown in Figure 6C evaluated by RT-qPCR and ELISA, as well as in Figure 6D by 
Western blotting, synthetic dsRNA polyI:C-induced IL-33 mRNA expression and protein 
production were markedly blocked by TLR3 antibody and TIR-domain-containing adaptor 
inducing interferon (TRIF) inhibitory peptide (Pepinh-TRIF), but not by TLR5 antibody or 
MyD88 inhibitory peptide (Pepinh-MYD), while extracted bacterial component flagellin-
induced IL-33 production was dramatically suppressed by TLR5 antibody and Pepinh-
MYD, but not by TLR3 antibody or Pepinh-TRIF, in corneal epithelial cells. The stimulated 
IL-33 induction by polyI:C or flagellin were also significantly blocked by IκB-ǂ inhibitor 
BAY11-7082 or NF-κB activation inhibitor quinazoline. Further study has shown that NF-κB 
was dramatically activated with p65 protein nuclear translocation in corneal epithelial cells 
exposed to polyI:C or flagellin for 4 hours, as evaluated by Western blot analysis and 
immunofluorescent staining. BAY 11 selectively inhibits the phosphorylation and 
degradation of IκB-ǂ, blocked the nuclear translocation of NF-κB p65 protein. NF-κB 
activation inhibitor quinazoline also blocked the p65 nuclear translocation. These findings 
demonstrate a novel phenomenon that a newly defined pro-allergic cytokine IL-33 is largely 
induced by microbial components through TLR and NF-κB signaling pathways in human 
corneal epithelium. This suggests that human ocular mucosal epithelium plays an important 
role in initiating Th2-dominant allergic inflammation via innate immune responses.  
In a clinical study, we have tested conjunctival impression cytology specimens obtained from 8 
patients with active atopic conjunctivitis and 8 normal subjects by RT-qPCR (Figure 7). The 
mRNA levels of TSLP, TSLPR, OX40L, OX40, IL-33 and ST2 were found to be significantly 
elevated in the atopic group compared with the normal control subjects, suggesting a potential 
role of TSLP/TSLPR/OX40L/OX40 and IL-33/ST2 signaling pathways in allergic 
conjunctivitis (Figure 7A). In SRW pollen induced EAC mice, the transcripts and proteins of 
IL-33, ST2, and IL-1 receptor accessory protein (IL1RAP) were also found to be significantly 
increased in the corneal epithelium, conjunctiva and CLN, as evaluated by RT-qPCR (Figure 
7B) and immunostaining (Figure 7C). IL-33, ST2 and TLRs could become novel biomarkers 
and molecular targets for the intervention to treat allergic inflammatory diseases. 
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Fig. 7. The role of IL-33 in allergic disease. A. Elevated mRNA levels of TSLP and IL-33 
signaling molecules in conjunctiva of atopic patients compared with normal subjects by RT-
qPCR. * P<0.05, **P<0.01, n=8. B. The mRNA levels of IL-33, ST2 and IL1RAP in corneal 
epithelium (Cornea), conjunctiva (Conj) and cervical lymph nodes (CLN) of in BALB/c mice 
with PBS-treated mice as controls. * P<0.05, n=3. C. Immunostaining images showing the 
stimulated IL-33 in ocular surface of EAC BALB/c mice with untreated mouse control and 
isotype IgG negative control. 
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7. Th17 pathway links innate and adaptive immunity 
Th17 has been recently identified as a new T helper cell subset. CD4+ T helper (Th) cells now 
include three different types based on their cytokine signatures: interferon-Ǆ (IFN-Ǆ)-
secreting Th1, IL-4, -5, and -13-secreting Th2 [75], and IL-17-producing Th17 cells [76]. Th17 
cells have been recognized to be key effector T cells in a variety of human inflammatory and 
autoimmune diseases as well as experimental animal models [77, 78]. The IL-17 family 
includes 6 members (IL17A-F). IL-17A (also known as IL-17) and IL-17F are the founding 
members of the IL-17 cytokine family. The genes encoding IL-17A and IL-17F are localized 
in the same chromosomal region in mice and in humans. But IL-17F has significantly weaker 
biological activity than IL-17A [79, 80]. IL-17E, also known as IL-25, is produced by Th2 cells 
and mast cells. In contrast, IL-17B, IL-17C and IL-17D have not been well investigated [81, 
82]. The receptor for IL-17A (IL-17R or IL-17RA) is a single-pass transmembrane protein of 
approximately 130 kDa. Four additional receptors (IL-17RB-RE) have been identified, but 
are not well characterized. IL-17RC was recently identified to be a receptor for IL-17F [83]. It 
has been reported that Th17 cells also produce IL-22 [84, 85] and CC-chemokine attractant 
ligand 20 (CCL20) [86] in mice and humans. Therefore, distinct from Th1 and Th2 cells, Th17 
cells produce a unique and expanding array of pro-inflammatory cytokines.  
Compelling evidence has demonstrated that the differentiation of Th17 cells from naïve 
CD4+ T cells is initiated by cytokines IL-6 or TGF-ǃ, and expanded by cytokines IL-23, IL-1ǃ 
and IL-21. IL-6 or TGF-ǃ was proposed as a major initiator necessary for Th17 differentiation 
[87-89]. IL-23 was the first cytokine shown to selectively regulate IL-17 expression [90, 91], 
but it might not be required for the initial differentiation of Th17 cells in vivo [92]. Recently, 
IL-1ǃ was found to promote Th17 cell development and proliferation in the presence of 
TGF-ǃ and IL-6 [88]. IL-21, produced by activated T cells and natural killer (NK) cells [93], 
may be required for full commitment of Th17 cells [94, 95]. Hence IL-23, IL-1ǃ and IL-21 
may possibly maintain and expand the differentiated Th17 cells in the presence of IL-6 and 
TGF-ǃ [88]. Furthermore, STAT3 has been found to mediate the initiation of Th17 cell 
differentiation by these inducing cytokines [87]. Activation of STAT3 induces the expression 
of retinoic-acid-receptor-related orphan receptor-ǂ (RORǂ) and RORǄt [96],  two 
transcription factors that promote the Th17-cell-associated gene-expression program, 
leading to the production of IL-17, IL-17F, IL-22 and CCL20. 
Using peripheral CD4+ T cell isolated from mouse spleen and cervical lymph nodes, our 
team evaluated the differential effects of these inducing cytokines in promoting Th17 
differentiation [97]. The results showed that IL-6 and TGF-ǃ1, only minimally induced IL-17 
production at both mRNA and protein levels. In the presence of IL-6 and TGF-ǃ1, IL-23 was 
the strongest stimulator of the Th17 signature cytokines IL-17A and IL-17F, IL-22, and 
chemokine CCL20, as well as STAT3 among the 3 expanding cytokines IL-23, IL-1ǃ and IL-
21. In the 4 cytokine system, IL-1ǃ stimulated much higher levels of IL-17 family cytokines, 
1.5-2 fold greater than IL-21 in the presence of TGF-ǃ1, IL-6 and IL-23. These findings 
suggest that TGF-ǃ1 and IL-6 initiate low level differentiation of Th17 cells; and their 
maintenance and development need other expanding factors, among which IL-23 plays a 
potent role and IL-1ǃ amplifies this expansion further in Th17 differentiation [97].  
A variety of mucosal epithelia have been found to produce Th17 inducing cytokines, 
including TGF-ǃ1, IL-6, IL-23, and IL-1ǃ [98, 99]. IL-1ǃ is a well recognized proinflammatory 
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cytokine produced by mucosal epithelia in response to stress, infection or wounding. In an 
attempt to mimic known stressors of the ocular surface, we measured production of Th17 
inducing cytokines in cultured HCECs in response to hyperosmotic stress, microbial 
components and inflammatory cytokines. 
The ocular surface epithelium is subjected to hyperosmotic stress in dry eye conditions. 
Exposure of human epithelial cells to hyperosmotic stress has been noted to activate 
mitogen-activated protein kinase pathways and stimulate production of pro-inflammatory 
cytokines, such as IL-1ǃ, TNF-ǂ, and IL-8 [100]. We have also observed that TGF-ǃ1, IL-6 
and IL-23 were highly induced in the corneal epithelium in response to hyperosmotic stress.  
We evaluated the expression and production of Th17-inducing cytokines by HCECs in 
response to 9 extracted or synthetic microbial components that are ligands of TLRs 1-9, 
respectively. TGF-ǃ1, IL-6, IL-23, and IL-1ǃ expression and production were found to be 
largely induced by polyI: C, flagellin, and R837, the respective ligands for TLRs3, 5 and 7, 
representing viral or bacterial infections. Among these TLR agonists, polyI:C was the 
strongest stimulator of Th17 inducing cytokines by HCECs.  
Hyperosmotic stress and microbial components also promoted production of pro-
inflammatory cytokines including TNF-ǂ, which plays an important role in ocular surface 
disease [100, 101]. Consequently, TNF-ǂ stimulus was found to markedly induce TGF-ǃ1, 
IL-6, IL-23, and IL-1ǃ. 
Based on our findings that among TLR ligands, polyI:C is the potent stimulator of Th17 
inducing cytokines, and that TNF-ǂ is a representative pro-inflammatory factor, we evaluated 
the Th17 inducing capacity of conditioned media (CM) of HCECs treated with polyI:C and 
TNF-ǂ [97]. It has been observed that Th17 cell differentiation was significantly stimulated in 
CD4+ T cells exposed to the 50% conditioned media of HCECs challenged by polyI:C (CM-
polyI:C) or TNF-ǂ (CM-TNF-ǂ) when compared with media from untreated cultures. 
As shown in Figure 8A-E, the mRNA levels of IL-17A, IL-17F, IL-22, CCL-20 and STAT3 
were significantly higher in CD4+ T cells treated with CM-polyI:C or CM-TNF-ǂ for 4 days 
compared with the control medium or conditioned media of HCEC culture without any 
stressors (CM-Control, all P<0.05, n=3). IL-17 protein levels in the supernatants of CD4+ T 
cells exposed to CM-polyI:C or CM-TNF-ǂ for 4 days (Figure 8F) were also significantly 
higher than the media (both P<0.01, n=3) and CM (P<0.05, n=3) controls. Furthermore, the 
number of IL-17-producing cells differentiated from CD4+ T cells, determined by ELISPOT 
bioassay (Figure 8G, 8H), displayed the same pattern to the induction of IL-17 mRNA and 
protein. The numbers of IL-17-producing cells were stimulated by CM-polyI:C or CM-TNF-
ǂ, to the levels similar to that seen in the 3-cytokine system (TGF-ǃ1+IL-6+IL-23), suggesting 
that cytokines in the conditioned media of HCECs exposed to polyI:C or TNF-ǂ were 
capable to promote Th17 cell expansion to levels induced by IL-6+TGF-ǃ1+IL-23. It suggests 
that the Th17 cells can be indeed promoted by factors produced by corneal epithelium in 
response to a variety of inflammatory stimuli [97].  
8. Th17-mediated inflammation in dry eye 
Dry eye is the second most common problem of patients seeking eye care, and is 
characterized by eye irritation symptoms and blurred vision. The prevalence of dry eye  
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Fig. 8. Induction of Th17 differentiation of murine CD4+ T cells cultured in RPMI media 
containing 50% conditioned media (CM) of HCECs. A-E. Real-time PCR data showing the 
relative fold of mRNA of Th17 associated cytokines (IL-17A, IL-17F, IL-22, CCL-20) and 
regulator STAT3 in CD4+ T cells incubated for 4 days with 50% of conditioned media of 
HCECs irritated by polyI:C (CM-PolyI:C) or TNF-ǂ (CM-TNF-ǂ) for 48 hrs. F. Luminex 
immunobead assay showing IL-17 concentration in the supernatant of CD4+ T cells receiving 
the same treatment for 4 days. G & H. ELISPOT bioassay showing the spots/3x105 
cells/well, representing the numbers of IL-17-producing T cells, in CD4+ T cells treated with 
CM-PolyI:C, CM-TNF-ǂ, or 3 cytokines (TGF-ǃ1+IL-6+IL-23) for 7 days. Results shown are 
mean ± SD of 3-5 independent experiments. *, P < 0.05; **, P <0.01; ***, P < 0.001 each treated 
groups vs. media control. ^, P < 0.05; ^^, P <0.01; ^^^, P < 0.001 CM-PolyI:C or CM-TNF-ǂ 
groups vs. CM-control group. 
increases with age, 6% at the age of 40, and 15-25% in the population over the age of 65. 
Among dry eye patients, 11% have been estimated to have the systemic autoimmune 
condition Sjögren’s syndrome, a severe and potentially blinding condition. Dry eye is a 
potent stimulus of both innate and adaptive immune systems. At the nexus of the dry eye 
inflammatory/immune response is the dynamic interplay between the ocular surface 
epithelia and bone marrow derived immune cells. On the one hand, the ocular surface 
epithelial cells play a key initiating role in this inflammatory reaction, while on the other 
hand they are targets of cytokines that are produced by activated T cells that are recruited to 
the ocular surface in response to dry eye.  
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Dry eye has been demonstrated to cause inflammation of the ocular surface, evidenced by 
increased levels of inflammatory cytokines (IL-1, IL-6, and TNF-ǂ) in the tear fluid, corneal 
and conjunctival epithelium, and an increased infiltration of dendritic cells and T 
lymphocytes in the conjunctiva [102-105]. Recently, increased levels of IL-17, IL-23 and IL-6 
were found in saliva and salivary glands biopsies obtained from patients with the severe 
autoimmune dry eye condition, Sjögren’s syndrome [106]. The increased matrix 
metalloproteinase (MMP) 9 and disrupted barrier function were observed in human [107] 
and murine dry eye [108]. Recently, our group has found increased expression of Th17 
associated cytokines and IL-17-producing cells in human and experimental murine dry eye 
[108, 109]. Increased expression of Th17 cytokine IL-17A was observed in corneal and 
conjunctival epithelia of the dry eye mice. Since IL-17A is produced by T cells, not by 
epithelial cells, the Th17 reaction of the ocular surface is likely due to CD4+ T cells, which 
have previously been found to infiltrate ocular surface tissues following experimental 
desiccating stress [110, 111]. Antibody neutralization of IL-17 ameliorated experimental dry 
eye-induced corneal epithelial barrier dysfunction and decreased the expression of MMP-3 
and -9 [108]. These findings provide clear evidence that changes in the ocular surface 
environment, such as Th17-inducing cytokines, following desiccating stress are capable of 
inducing Th17 differentiation [112], which plays an important role in dry eye disease. 
Th17 differentiation was also found to be mediated through a dendritic cell-mediated 
pathway. DCs have an important function in Th17 cell differentiation. They are antigen-
presenting cells specialized to activate CD4+ T cells and through their interaction with CD4+ 
T cells to initiate primary immune responses. Furthermore, when primed, certain DCs 
express a high-level of Th17 inducing cytokines, including IL-6, TGF-ǃ, IL-23 and IL-1 [113].  
We found that efficient differentiation of CD4+ T cells to IL-17 producers required the 
combination of ocular surface epithelium from dry eye mice and dendritic cells. CD4+ T cells 
that were co-cultured with ocular epithelial explants from desiccating stress-induced dry 
eye mice and dendritic cells were found to express increased mRNA levels of Th17 
cytokines (IL-17A, IL-17F, IL-22) and chemokine (C-C motif) ligand 20 (CCL20) (Figure 9A), 
as well as to produce and release IL-17A (Figure 9B & 9D), but not Th1 cytokine IFN-Ǆ 
(Figure 9C). Exposure of dendritic cells to conditioned media from ocular surface explants of 
dry eye mice did not sufficiently activate these cells to promote T cell differentiation. The 
possible explanations for these findings include the need for direct contact between these 
cells, more efficient activation of cytokines such as TGF-ǃ1 produced by the ocular surface 
epithelial cells or insufficient concentrations of Th17 inducing factors in the explants 
conditioned media.  
The transcription factor RORǄt was identified as a candidate master regulator that drives 
Th17 cell lineage differentiation [96]. Expression of RORǄt is induced by TGF-ǃ or IL-6, and 
overexpression of Ǆt was found to promote Th17-cell differentiation when both Th1- and 
Th2-cell differentiations were blocked. In a model of experimental autoimmune 
encephalomyelitis, mice with RORǄt-deficient T cells were found to have attenuated 
autoimmune disease and lacked tissue-infiltrating Th17 cells [96]. We found robust up-
regulation (up to 100 fold) of the level of Th17 cell transcription factor-RORǄt in T cells co-
cultured with desiccated ocular surface tissues and dendritic cells (Figure 9E). This provides 
further evidence of the potent Th17 prone environment induced by desiccation. 
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Fig. 9. Th17 differentiation of CD4+ T cells induced by the co-culture with dendritic cells (DCs) 
in the presence of cornea and conjunctival tissues of C57BL/6 mice subjected to desiccating 
stress. A. Real-time PCR data showing the relative mRNA expression (x-fold) of Th17 
cytokines (IL-17A, IL-17F, IL-22, CCL-20) in CD4+ T cells (3x105 cells/ well) co-cultured for 1, 2, 
4 days with DCs (T cell+DC), or with DCs and cornea and conjunctival explants from non-
stressed control mice (T cell+DC+NS) or from mice desiccating stressed for 10-day (T 
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cell+DC+DS), (n=4). B & C. ELISPOT bioassay showing the numbers of IL-17 or IFN-Ǆ- 
producing cells in these 3 groups. D. IL-17 concentration in the supernatant of CD4+ T cells co-
cultured with DCs for 4 days in absence or presence of corneal and conjunctival explants from 
non-stressed and 10 day desiccating stressed mice. E. Real-time PCR showing the relative 
mRNA expression of RORǄt in CD4+ T cells co-cultured for 1, 2, 4 days in 3 conditions. Data 
are presented as mean ± SD of 3 or 4 independent experiments. *P<0.05, **P<0.01, ***P<0.001.  
 
Fig. 10. The inflammatory effects of IL-17 on HCECs. Primary HCECs (5×105 cells/well) 
were treated with recombinant human IL-17A at 10 ng/ml for 4-48 hours with or without 
NF-кB activation inhibitor quinazoline (NFκB-I, 5µM). The pro-inflammatory cytokines 
(TNF-ǂ, IL-1ǃ and IL-6) and chemokine IL-8 were measured by RT-qPCR for mRNA (A) and 
by ELISA or Luminex immunobead assays in culture supernatants (B). Results shown are 
mean ± SD of 4 independent experiments. * P < 0.05, ** P< 0.01. 
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IL-17 producing T cells are distinct from Th1 cells. Analysis of the expression of 
transcription factors showed clearly that IL-17-producing T cells expressed neither GATA-3 
nor T-bet and its target Hlx, which were typically expressed by IFN-Ǆ-producing Th1 cells 
[88]. In the T cells co-cultured with desiccated ocular surface tissues and dendritic cells, we 
observed the lower expression of Th1 associated factors (IL-2, T-bet) and Th2 associated 
factors (IL-4, IL-13, GATA-3). There was no change in production of IFN-Ǆ and IL-12 
transcripts as well as in the number of IFN-Ǆ-producing CD4+T cells in this co-culture 
system. Taken together, these findings indicate that desiccating stress may selectively 
promote the Th17 pathway, a finding that is consistent with the increased level of IL-17 in 
dry eye disease [108].  
IL-17 initiates pro-inflammatory effects by binding to the IL-17 receptor (IL-17R), which is 
expressed by a variety of cell types including epithelial, endothelial, and fibroblastic stromal 
cells [81, 114]. As shown in Figure 10, recombinant human IL-17A (10 ng/ml) significantly 
increased mRNA levels (2-4 fold) of proinflammatory cytokines (TNF-ǂ, IL-1ǃ and IL-6) and 
chemokine IL-8 expressed by HCECs. These stimulatory responses to IL-17A were confirmed 
by 4-7 fold increases at protein levels. The stimulated production of these inflammatory 
cytokines and chemokine was significantly suppressed at both mRNA (all P<0.05, n=4) and 
protein levels (P<0.05 or 0.01) by NF-κB activation inhibitor quinazoline [115], indicating NF-
κB pathway is involved in the inflammatory effect of IL-17 on mucosal epithelium. 
These findings demonstrate that desiccating stress stimulates the expression and production 
of Th17 inducing cytokines by corneal and conjunctival epithelia, and that desiccation 
creates an environment promoting Th17 differentiation through a dendritic cell-mediated 
pathway. We hypothesize that Th17 inducing cytokines produced by the ocular epithelium 
may participate in Th17 differentiation in three ways: (1) activation of immature dendritic 
cells on the ocular surface; (2) direct transfer to the lymph node in lymphatic liquid; or (3) 
direct promotion of differentiated Th17 cells that infiltrate the ocular surface. 
9. Conclusion 
This chapter focused on recent breakthroughs in ocular mucosal immunology, including the 
discoveries of TLR signaling in innate immunity, novel epithelium-derived pro-allergic 
cytokines TSLP and IL-33, and a new Th17 cell population in adaptive immunity. One of 
important breakthroughs is a discovery of a novel mechanism by which short ragweed 
pollen, serving as a functional TLR4 agonist, induces TSLP/OX40L/OX40 signaling to 
trigger Th2-dominant allergic inflammation via TLR4-dependent innate immunity 
pathways. All these advances provide compelling evidence that mucosal epithelium actively 
participate, as initiators, mediators and regulators, in innate and adaptive immune 
responses for host defense, in addition to physical barrier function. These novel signaling 
molecules may be critical for allergic, inflammatory and autoimmune diseases on mucosal 
ocular surface, and may become potential molecular targets for new therapies to treat these 
ocular diseases.  
10. Abbreviations used in this chapter 
CLN: cervical lymph nodes; DAMP: damage-associated molecular patterns; DC: dendritic 
cell; dsRNA: double stranded RNA; EAC: experimental allergic conjunctivitis; HCECs: 
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human corneal epithelial cells; IL: interleukin; MyD88: myeloid differentiation primary 
response gene 88; MyD88-/-: MyD88 knockout mice; LPS: lipopolysaccharide; NF-κB: nuclear 
factor kappa B; PBS: phosphate buffered saline; PGN: peptidoglycan; PAMP: pathogen-
associated molecular patterns; PCR: polymerase chain reaction; polyI:C: polyinosinic-
polycytidylic acid; PRR: pattern recognition receptor; R837: imiquimod; RT-qPCR: reverse 
transcription and quantitative real-time PCR; ROR: retinoic-acid-receptor-related orphan 
receptor; SRW: short ragweed; SRWe: aqueous extract of defatted short ragweed pollen; 
ssRNA: single stranded RNA; TGF-β: transforming growth factor; Th1: T helper cell type 1; 
Th17: T helper cell producing IL-17 family; Th2: T helper cell type 2; TLR: Toll-like receptor; 
Tlr4-d: Tlr4 gene deficient; TRIF: TIR-domain-containing adaptor inducing interferon; TSLP: 
thymic stromal lymphopoietin;  TSLPR: TSLP receptor. 
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